DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: VELCADE

Summary for Tradename: VELCADE

Patents:8
Applicants:1
NDAs:1
Suppliers: see list1
2013 Sales:$621,800,000
drug
patent expirations by year for
 VELCADE

Pharmacology for Tradename: VELCADE

Drug ClassProteasome Inhibitor
Mechanism of ActionProteasome Inhibitors

Clinical Trials for: VELCADE

Study on the Safety and Effectiveness of VELCADEĀ® in the Treatment of Graft-Versus-Host Disease
Status: Completed Condition: Graft-versus-Host Disease

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
Status: Active, not recruiting Condition: Multiple Myeloma

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Status: Completed Condition: Multiple Myeloma

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Status: Active, not recruiting Condition: Lymphoma

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Status: Completed Condition: Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma

Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone
Status: Active, not recruiting Condition: Prostate Cancer

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Status: Completed Condition: Multiple Myeloma; Non-Hodgkin's Lymphoma

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Status: Active, not recruiting Condition: Multiple Myeloma

Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma
Status: Active, not recruiting Condition: Mantle Cell Lymphoma; Lymphoma

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML
Status: Completed Condition: Acute Myelogenous Leukemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes<disabled><disabled>
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes<disabled><disabled>
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes5,780,454<disabled>Y<disabled>
Millennium Pharms
VELCADE
bortezomib
INJECTABLE;INTRAVENOUS, SUBCUTANEOUS021602May 13, 2003RXYes6,083,903<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VELCADE

Drugname Dosage Strength RLD Submissiondate
bortezomibFor Injection3.5 mg/vialVelcade11/20/2008

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc